1. Characterising a SOX2+ OLIG2+ glioma stem cell using Crispr-engineered fluorescent reporters in primary patient-derived GBM and DIPG cells. (12th October 2019) Authors: Finlay, Jack; Hallou, Clement; Dewari, Pooran; Pollard, Steven; Pathania, Manav; Bulstrode, Harry; Rowitch, David Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 4 Page Start: iv9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. (2nd April 2016) Authors: Garros-Regulez, Laura; Aldaz, Paula; Arrizabalaga, Olatz; Moncho-Amor, Veronica; Carrasco-Garcia, Estefania; Manterola, Lorea; Moreno-Cugnon, Leire; Barrena, Cristina; Villanua, Jorge; Ruiz, Irune; Pollard, Steven; Lovell-Badge, Robin; Sampron, Nicolas; Garcia, Idoia; Matheu, Ander Journal: Expert opinion on therapeutic targets Issue: Volume 20:Number 4(2016:Apr.) Page Start: 393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. STEM-05. NEURAL G0: A NOVEL QUIESCENT-LIKE STATE IN PROLIFERATING HUMAN NEURAL STEM AND GLIOBLASTOMA TUMOR CELLS. (11th November 2019) Authors: Feldman, Heather; Arora, Sonali; Hoellerbauer, Pia; Pollard, Steven; Patel, Anoop; Plaisier, Christopher; Paddison, Patrick Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi234 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗